CN1329509A - 用于由靶细胞表达因子viii的腺伴随病毒载体 - Google Patents

用于由靶细胞表达因子viii的腺伴随病毒载体 Download PDF

Info

Publication number
CN1329509A
CN1329509A CN99814128A CN99814128A CN1329509A CN 1329509 A CN1329509 A CN 1329509A CN 99814128 A CN99814128 A CN 99814128A CN 99814128 A CN99814128 A CN 99814128A CN 1329509 A CN1329509 A CN 1329509A
Authority
CN
China
Prior art keywords
factor viii
aav
factor
cell
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99814128A
Other languages
English (en)
Chinese (zh)
Inventor
L·B·科特
P·C·克洛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avigen Inc
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27379851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1329509(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avigen Inc filed Critical Avigen Inc
Publication of CN1329509A publication Critical patent/CN1329509A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN99814128A 1998-10-20 1999-10-19 用于由靶细胞表达因子viii的腺伴随病毒载体 Pending CN1329509A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10499498P 1998-10-20 1998-10-20
US60/104,994 1998-10-20
US12597499P 1999-03-24 1999-03-24
US60/125,974 1999-03-24
US09/364,862 1999-07-30
US09/364,862 US6221349B1 (en) 1998-10-20 1999-07-30 Adeno-associated vectors for expression of factor VIII by target cells

Publications (1)

Publication Number Publication Date
CN1329509A true CN1329509A (zh) 2002-01-02

Family

ID=27379851

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99814128A Pending CN1329509A (zh) 1998-10-20 1999-10-19 用于由靶细胞表达因子viii的腺伴随病毒载体

Country Status (11)

Country Link
US (1) US6221349B1 (https=)
EP (1) EP1124583A4 (https=)
JP (1) JP2002527493A (https=)
KR (1) KR20010082234A (https=)
CN (1) CN1329509A (https=)
AU (1) AU757688B2 (https=)
BR (1) BR9914643A (https=)
CA (1) CA2348068A1 (https=)
IL (1) IL142721A0 (https=)
MX (1) MXPA01004067A (https=)
WO (1) WO2000023116A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103215308A (zh) * 2013-02-01 2013-07-24 中国科学院苏州生物医学院工程技术研究所 表达重组人fviii的整合质粒、细胞株及其构建方法和应用
CN104087613A (zh) * 2014-06-30 2014-10-08 中国科学院苏州生物医学工程技术研究所 基于aav-itr的基因表达微载体及其构建方法和应用
CN108093639A (zh) * 2015-04-16 2018-05-29 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
CN108368521A (zh) * 2015-08-06 2018-08-03 宾夕法尼亚州大学信托人 Glp-1和其在用于治疗代谢疾病的组合物中的用途
CN108602876A (zh) * 2015-11-13 2018-09-28 百深公司 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
CN108884145A (zh) * 2015-11-13 2018-11-23 百深公司 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
CN109328073A (zh) * 2016-02-23 2019-02-12 眼服务有限责任公司 用于治疗视网膜变性疾病的基因疗法
CN109562191A (zh) * 2016-04-15 2019-04-02 宾夕法尼亚州大学信托人 用于治疗血友病a的基因疗法
CN111876400A (zh) * 2020-08-06 2020-11-03 昆明理工大学 一种常温裂解酶Sly和编码此酶的多核苷酸
CN112384624A (zh) * 2018-05-15 2021-02-19 杜克大学 用于对阿克曼菌进行基因操纵的系统和方法
CN114269940A (zh) * 2019-07-03 2022-04-01 学校法人日本医科大学 用于产生包封核酸的aav中空颗粒的方法

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2265460A1 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Aav4 vector and uses thereof
US6436392B1 (en) * 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
EP1082413B1 (en) * 1998-05-28 2008-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Aav5 vector and uses thereof
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7122335B1 (en) 1999-06-08 2006-10-17 University Of Iowa Research Foundation Compounds and methods to enhance rAAV transduction
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
AU7879000A (en) * 1999-10-12 2001-04-23 University Of North Carolina At Chapel Hill, The Adeno-associated virus vectors encoding factor viii and methods of using the same
AU1775901A (en) * 1999-11-17 2001-05-30 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
CA2400634A1 (en) * 2000-02-17 2001-08-23 Chester Li Genetic modification of the lung as a portal for gene delivery
US6855314B1 (en) * 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
WO2002055110A2 (en) * 2000-10-25 2002-07-18 Genzyme Corp Methods for treating blood coagulation disorders
US20020159978A1 (en) * 2001-02-06 2002-10-31 James Allen Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
WO2002071843A1 (en) * 2001-03-14 2002-09-19 Genteric, Inc. Recombinant adeno-assocaited virus-mediated gene transfer via retroductal infusion of virions
CN1520259A (zh) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
ATE437221T1 (de) * 2001-05-14 2009-08-15 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
US8241622B2 (en) * 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
EP1418810A4 (en) * 2001-08-03 2006-08-02 Us Gov Health & Human Serv TREATMENT OF HEMOPHILIA ORAL
PT1567641E (pt) 2001-08-24 2012-08-21 Uvic Industry Partnerships Inc Proaerolisina contendo sequência de activação de proteases e métodos de uso para o tratamento do cancro da próstata
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US7419817B2 (en) * 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
KR100535325B1 (ko) * 2002-09-24 2005-12-09 한국생명공학연구원 Ａａｖ 유전자 전달체 제조용 헬퍼 플라스미드
US20040092008A1 (en) * 2002-11-12 2004-05-13 Snyder Richard O. Recombinant AAV vectors for gene therapy of hemophilia A
JP2007524379A (ja) * 2003-03-31 2007-08-30 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン 上皮ナトリウムチャンネル関連障害のＰｈａｒｍｉｃｏ−遺伝子治療
US7963956B2 (en) * 2003-04-22 2011-06-21 Antisense Pharma Gmbh Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique
WO2005017101A2 (en) 2003-05-19 2005-02-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Avian adenoassociated virus (aaav) and uses thereof
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2004111246A1 (en) * 2003-06-19 2004-12-23 Peter Bromley Protein production system
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2005056807A2 (en) 2003-12-04 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Bovine adeno-associated viral (baav) vector and uses thereof
WO2006029196A1 (en) * 2004-09-08 2006-03-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of H Ealth Transcytosis of adeno-associated viruses
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
CA2604299A1 (en) * 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
US8283151B2 (en) * 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP4154903A1 (en) * 2008-04-22 2023-03-29 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
DK2675902T3 (da) 2011-02-17 2019-06-03 Univ Pennsylvania Sammensætninger og fremgangsmåder til at ændre vævsspecificitet og forbedre aav9-medieret genoverførsel
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
RS61039B1 (sr) 2013-09-12 2020-12-31 Biomarin Pharm Inc Aav vektori koji sadrže gen koji kodira faktor viii
DK3193911T5 (da) * 2014-07-25 2024-10-14 Csl Behring Gmbh Forbedrede faktor VII-præparater til brug ved behandling af hæmofili A
CA3237630A1 (en) * 2014-08-13 2016-02-18 The Children's Hospital Of Philadelphia An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders
SG11201703148TA (en) * 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
RU2742352C2 (ru) 2015-09-24 2021-02-05 Байомарин Фармасьютикал Инк. Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции
CA3002524A1 (en) 2015-10-28 2017-05-04 Sangamo Therapeutics, Inc. Liver-specific constructs, factor viii expression cassettes and methods of use thereof
US10385320B2 (en) 2015-12-02 2019-08-20 The Board Of Trustees Of The Leland Stanford Junior University Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US10179176B2 (en) 2016-02-16 2019-01-15 The Board Of Trustees Of The Leland Stanford Junior University Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
CA3198936A1 (en) 2016-03-07 2017-09-14 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
JP7455579B2 (ja) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途
JOP20190269A1 (ar) * 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
TW202545984A (zh) * 2017-08-09 2025-12-01 美商生物化學醫療公司 核酸分子及其用途
MX2020008932A (es) 2018-02-27 2020-10-01 Univ Pennsylvania Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
US11608510B2 (en) 2018-03-30 2023-03-21 The Board Of Trustees Of The Leland Stanford Junior University Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
JP7603013B2 (ja) * 2019-02-20 2024-12-19 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー
PE20220014A1 (es) 2019-04-29 2022-01-11 Univ Pennsylvania Nuevas capsides de aav y composiciones que las contienen
AR118928A1 (es) * 2019-05-14 2021-11-10 Biomarin Pharm Inc Métodos de redosificación de vectores de terapia génica
JP2023537070A (ja) 2020-08-07 2023-08-30 アミカス セラピューティックス インコーポレイテッド 小胞を標的とするタンパク質及びその使用
IL300410A (en) 2020-08-14 2023-04-01 Univ Pennsylvania Novel AAV capsids and compositions containing them
IL302127A (en) 2020-10-18 2023-06-01 Univ Pennsylvania An improved adeno-associated virus (AAV) vector and its uses
AU2021369793A1 (en) 2020-10-29 2023-06-08 The Trustees Of The University Of Pennsylvania Aav capsids and compositions containing same
TW202309066A (zh) 2021-04-27 2023-03-01 賓州大學委員會 衍生自豬的腺相關病毒衣殼及其用途
JP2024524270A (ja) 2021-06-23 2024-07-05 アスクバイオ・ユーケー・リミテッド 調節性核酸配列
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
JP2025542309A (ja) 2022-12-20 2025-12-25 ナノセル セラピューティクス ホールディングス ビー．ブイ． 組み込み型ウイルスベクターおよび自己不活性化ウイルスベクターならびにその構築物および使用
EP4389899A1 (en) 2022-12-22 2024-06-26 Synpromics Ltd. Regulatory nucleic acid sequences
WO2025239324A1 (ja) * 2024-05-13 2025-11-20 中外製薬株式会社 遺伝子改変非ヒト動物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4886876A (en) 1983-03-31 1989-12-12 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides
WO1985001961A1 (en) 1983-10-28 1985-05-09 Genetics Institute Production of factor viii and related products
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
DE3538181A1 (de) 1985-10-26 1987-04-30 Messer Griesheim Gmbh Vorrichtung zur automatischen begrenzung des fuellstandes kryogener fluessigkeiten
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FI98829C (fi) 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5426029A (en) 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5149637A (en) 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
WO1988009809A2 (en) 1987-06-12 1988-12-15 Cetus Corporation Cell system for expression of recombinant protein without production of virus
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
ZA909167B (en) 1989-11-17 1993-10-15 Chiron Corp Protein complexes having Factor VIII:C activity and production thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
SE468050C (sv) 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
ATE185424T1 (de) 1991-07-29 1999-10-15 Serex Inc Differentielle bindungsaffinitäten und darauf beruhende dissoziationstestverfahren
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
CA2106260A1 (en) 1992-09-17 1994-03-18 Robert M. Kotin Human adeno-associated virus integration site dna and uses thereof
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1994011013A1 (en) 1992-11-13 1994-05-26 Duke University Chimeric blood coagulation proteins
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
CA2162497A1 (en) * 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
DE69433925T2 (de) 1993-06-10 2005-07-28 Bayer Corp. Vektoren und Zelllinien von Säugetieren mit erhöhter Produktivität
AU7676894A (en) 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
PT733103E (pt) 1993-11-09 2004-07-30 Targeted Genetics Corp Criacao de elevados titulos de vectores de aav recombinantes
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
AUPM901594A0 (en) 1994-10-26 1994-11-17 Ici Australia Operations Proprietary Limited Apparatus and process for loading upholes with explosives
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6342390B1 (en) 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
US5843742A (en) 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US6521225B1 (en) * 1996-09-06 2003-02-18 Chiron Corporation AAV vectors
US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
EP1082445A2 (en) * 1998-05-27 2001-03-14 Cell Genesys, Inc. Adeno-associated viral vector-mediated expression of factor viii activity

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103215308A (zh) * 2013-02-01 2013-07-24 中国科学院苏州生物医学院工程技术研究所 表达重组人fviii的整合质粒、细胞株及其构建方法和应用
CN103215308B (zh) * 2013-02-01 2015-12-23 中国科学院苏州生物医学工程技术研究所 表达重组人fviii的整合质粒、细胞株及其构建方法和应用
CN104087613A (zh) * 2014-06-30 2014-10-08 中国科学院苏州生物医学工程技术研究所 基于aav-itr的基因表达微载体及其构建方法和应用
CN108093639A (zh) * 2015-04-16 2018-05-29 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
CN108368521A (zh) * 2015-08-06 2018-08-03 宾夕法尼亚州大学信托人 Glp-1和其在用于治疗代谢疾病的组合物中的用途
CN108884145A (zh) * 2015-11-13 2018-11-23 百深公司 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
CN108602876A (zh) * 2015-11-13 2018-09-28 百深公司 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
CN108602876B (zh) * 2015-11-13 2022-07-05 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
CN108884145B (zh) * 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
CN109328073A (zh) * 2016-02-23 2019-02-12 眼服务有限责任公司 用于治疗视网膜变性疾病的基因疗法
CN109562191A (zh) * 2016-04-15 2019-04-02 宾夕法尼亚州大学信托人 用于治疗血友病a的基因疗法
CN112384624A (zh) * 2018-05-15 2021-02-19 杜克大学 用于对阿克曼菌进行基因操纵的系统和方法
CN114269940A (zh) * 2019-07-03 2022-04-01 学校法人日本医科大学 用于产生包封核酸的aav中空颗粒的方法
CN111876400A (zh) * 2020-08-06 2020-11-03 昆明理工大学 一种常温裂解酶Sly和编码此酶的多核苷酸
CN111876400B (zh) * 2020-08-06 2022-05-24 昆明理工大学 一种常温裂解酶Sly和编码此酶的多核苷酸

Also Published As

Publication number Publication date
BR9914643A (pt) 2001-12-11
AU1125600A (en) 2000-05-08
MXPA01004067A (es) 2003-03-10
EP1124583A1 (en) 2001-08-22
IL142721A0 (en) 2002-03-10
EP1124583A4 (en) 2002-04-17
JP2002527493A (ja) 2002-08-27
CA2348068A1 (en) 2000-04-27
AU757688B2 (en) 2003-03-06
KR20010082234A (ko) 2001-08-29
US6221349B1 (en) 2001-04-24
WO2000023116A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
CN1329509A (zh) 用于由靶细胞表达因子viii的腺伴随病毒载体
US7351577B2 (en) Adeno-associated vector compositions for expression of Factor VIII
US10792343B2 (en) Compositions and methods for treating MPSI
KR102910588B1 (ko) 합성 간-향성 아데노-연관 바이러스 캡시드 및 그의 용도
US7238674B2 (en) Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
JP2022159358A (ja) 最適化されたヒト凝固第ｉｘ因子遺伝子発現カセットおよびそれらの使用
JP7231922B2 (ja) Ｍｐｓ－ｉ関連失明の治療のためのａａｖ－ｉｄｕａベクター
JP2019506445A (ja) パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質
WO2001068888A2 (en) Production of chimeric capsid vectors
CN111876432B (zh) 一组肝靶向新型腺相关病毒的获得及其应用
JP7616668B2 (ja) Ｕｂｅ３ａ遺伝子および発現カセットならびにそれらの使用
US20040002159A1 (en) Methods for the production of chimeric adeno-associated virus (AAV) vectors, compositions of chimeric AAV vectors, and methods of use thereof
KR20230135093A (ko) T-세포를 표적화하는 aav 벡터
WO2024060463A1 (zh) 改进的人凝血因子viii基因表达盒及其应用
HK40118611A (zh) 合成嗜肝性腺相关病毒衣壳及其用途
HK40042501A (en) Compositions for treating mpsi
HK40042501B (en) Compositions for treating mpsi
BR112017027956B1 (pt) Vetores de vírus adenoassociado recombinante, uso e método de produção dos mesmos, e composição farmacêutica

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication